一、停复牌 1、渤海汽车：拟购买海纳川持有的北汽模塑51%股权、廊坊安道拓51%股权、智联科技100%股权和莱 尼线束50%股权，股票明日复牌。 2、邦基科技：拟通过向Riverstone Farm Pte. Ltd.发行股份及支付现金的方式购买其持有的北溪农牧、瑞 东伟力、鑫牧农牧、瑞东农牧（利津）、瑞东农牧（山东）、威力牧业（滨州）100%股权及派斯东 80%股权，股票复牌。 二、并购重组 1、泰禾智能：拟不超过5000万收购阳光优储100%股权，拓展工商业用户侧储能业务。 1、江波龙：子公司与闪迪签署合作备忘录，Sandisk（闪迪）系全球知名的存储解决方案提供，拥有领 先的存储技术和丰富的系统设计经验。 2、美的集团：拟以50亿元至100亿元回购股份。 3、东方盛虹：控股股东一致行动人拟5亿元-10亿元增持公司股份。 2、大族数控：发行境外上市股份备案申请材料获中国证监会接收。 3、三达膜：拟发行H股并在香港联交所上市。 4、兴齐眼药：盐酸利多卡因眼用凝胶Ⅲ期临床试验首例受试者入组。 5、善水科技：拟投资60亿元建设化工新材料项目。 6、飞龙股份：获得两家客户大功率数据中心专用电子水泵订单。 7、亚太 ...

股票代码：688505 股票简称：复旦张江 编号：临 2025-017 上海复旦张江生物医药股份有限公司 自愿披露关于注射用 FZ-P001 钠用于癌症术中恶性病变可视化 获得药物临床试验申请受理通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海复旦张江生物医药股份有限公司（以下简称"公司"）于近日收到国家药 品监督管理局核准签发的《受理通知书》，注射用 FZ-P001 钠（以下简称"该药 物"）用于癌症术中恶性病变可视化的 I 期临床试验申请获得受理。由于药品的 研发周期长、审批环节多，容易受到一些不确定性因素的影响，敬请广大投资者 谨慎决策，注意防范投资风险。现将相关情况公告如下： 一、药物的基本情况 受 理 号：CXHL2500576 申 请 人：上海复旦张江生物医药股份有限公司 审批结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 由于医药产品具有高科技、高风险、高附加值的特点，药品从临床前研究、 临床试验到商业化的周期长、环节多，容易受到一些不确定性因素的影响。敬请 ...

Core Viewpoint - Fudan Zhangjiang has received the acceptance notice from the National Medical Products Administration for its self-developed injectable FZ-P001 sodium, aimed at visualizing malignant lesions during cancer surgery, marking a significant step in the development of innovative surgical solutions for tumor removal [1] Company Summary - The injectable FZ-P001 sodium is classified as a Class 1 new chemical drug, with its active ingredient being a conjugate of folate receptor-targeting small molecules and photosensitizers [1] - The drug is intended to enhance the effectiveness of surgical resection of solid tumors by indicating the presence of malignant tissue and the status of surgical margins [1] - This marks the first human Phase I clinical trial application for the drug, focusing on evaluating its safety, tolerability, and pharmacokinetic characteristics in humans [1] Industry Summary - The development of FZ-P001 sodium represents an innovative approach in the field of oncology, particularly in improving surgical outcomes for cancer patients [1] - The approval for the clinical trial reflects the growing interest and investment in advanced therapeutic solutions within the pharmaceutical industry [1]

上海众辰电子科技股份有限公司 上海众辰电子科技股份有限公司（以下简称"公司"）为了进一步建立、健 全公司长效激励机制，吸引和留住优秀人才，充分调动公司员工的积极性，有效 地将股东利益、公司利益和核心团队个人利益结合在一起，使各方共同关注公司 的长远发展，在充分保障股东利益的前提下，按照收益与贡献对等的原则，实施 为保证本激励计划的顺利实施，现根据《中华人民共和国公司法》《中华人 民共和国证券法》《上市公司股权激励管理办法》等有关法律、法规和规范性文 件以及《上海众辰电子科技股份有限公司章程》（以下简称《公司章程》）《2025 年第二期限制性股票激励计划（草案）》（以下简称《激励计划（草案）》）的 相关规定，并结合公司的实际情况，特制定本办法。 四、考核机构 公司行政部按照本办法及董事会薪酬与考核委员会的考核安排负责具体实 施对个人的绩效考核。公司财务部按照本办法及董事会薪酬与考核委员会的考核 安排负责具体实施对公司的业绩考核。行政部、财务部对考核数据和考核结果的 真实性、准确性、完整性和及时性负责，向董事会薪酬与考核委员会报告考核结 果，接受董事会薪酬与考核委员会关于考核结果的质询。 董事会薪酬与考核委员会主 ...

长江商报消息 ●长江商报记者 沈右荣 A股公司上海医药的创新药研发平台复旦张江（688505.SH）面临雪上加霜的困境。 日前，复旦张江发布药品价格调整公告，自今年5月1日，公司调整抗肿瘤药物盐酸多柔比星脂质体注射 液（商标名：里葆多?）市场零售价格，相比此前中标价格降价幅度不低于35%。 复旦张江表示，本次价格调整，将导致2025年里葆多销售收入下降超过50%，可能导致产品出现亏损。 里葆多是复旦张江在售的三大核心产品之一，2024年为公司贡献了29%的营业收入。 复旦张江经营持续承压。2022年至2024年，公司营收净利连续三年双降。今年一季度，公司营业收入同 比增长逾20%，但扣除非经常性损益的净利润（简称"扣非净利润"）仍然小幅亏损。公司"烧钱"的经营 模式面临考验。 复旦张江为何对里葆多的市场零售价格进行调整？公司解释，2024年，里葆多首次被纳入国家集采目 录。根据国家组织药品联合采购办公室发布的《关于公布全国药品集中采购（GY-YD2024-2）中选结果 的通知》，本次集采的执行期间为各品种各地采购中选结果执行之日起至2027年12月31日。依据本次集 采的规则以及市场竞争格局的改变，将导致里葆 ...

Core Viewpoint - The company announces a price adjustment for its anti-tumor drug, Doxorubicin Liposome Injection, due to its inclusion in the national centralized procurement directory, which will lead to a significant reduction in sales revenue for 2025 [4][6]. Group 1: Drug Overview - The drug, Doxorubicin Liposome Injection, was launched in August 2009 and is the first domestic generic version of Doxil/Caelyx, utilizing advanced liposome technology for passive targeting [2]. - In 2024, the drug generated approximately RMB 210 million in sales, accounting for 29% of the company's total revenue [2]. - The drug is primarily used for treating Kaposi's sarcoma related to AIDS, as well as multiple myeloma, breast cancer, and ovarian cancer [2][3]. Group 2: Reasons for Price Adjustment - The drug has been included in the national centralized procurement list for the first time in 2024, with the execution period lasting until December 31, 2027 [4]. - The company plans to gradually reduce the market retail price by no less than 35% starting from May 1, 2025, in response to the new procurement rules and market competition [4]. Group 3: Company Measures - The company will maintain long-term cooperation with existing suppliers and ensure stability in its production and quality control processes [5]. - It will optimize its marketing network and focus on developing new markets, particularly in private and profit-oriented medical institutions [5]. - The company aims to increase R&D investment to ensure continuous revenue contributions from other products while accelerating the commercialization of new products in advantageous areas [5]. Group 4: Impact of Price Adjustment - The price adjustment is expected to adversely affect the sales revenue of Doxorubicin Liposome Injection in the second quarter of 2025 and beyond, with an anticipated decline of over 50% in annual sales revenue [6]. - This decline may lead to a risk of single-product losses for the drug in 2025 [6].

Group 1 - National Integrated Circuit Industry Fund plans to reduce its stake in Jiangbolong by no more than 4,159,815 shares, accounting for 1.00% of the total share capital, between May 27, 2025, and August 26, 2025 [1] - The reduction is due to the fund's operational management needs and will be executed through centralized bidding at market prices [1] - The implementation of this reduction plan will not lead to a change in the company's control or significantly impact its governance structure and ongoing operations [1] Group 2 - Haitai Weiye has received approval from the China Securities Regulatory Commission for its H-share issuance, planning to issue no more than 710.52 million overseas listed ordinary shares [2] - The listing will take place on the main board of the Hong Kong Stock Exchange, but the matter still carries uncertainties [2] Group 3 - Fudan Zhangjiang announced a price reduction of at least 35% for its Doxorubicin Liposome Injection starting May 1, 2025, which is expected to negatively impact sales revenue [3] - The drug generated approximately RMB 210 million in sales for the year 2024, representing 29% of the company's total sales revenue [3] - The price adjustment may lead to a risk of single product loss for the drug in 2025 [3] Group 4 - Xinyuan Technology's director expressed inability to guarantee the authenticity and completeness of the 2024 annual report and related financial documents, citing significant issues identified by the audit firm [4] - The company has received a notice of investigation from the securities regulatory authority, and the audit report issued was unable to express an opinion [4] Group 5 - ST Xinchao announced that its stock will be suspended from trading starting May 6, 2025, due to the inability to disclose the audited 2024 annual report and the 2025 Q1 report within the legal timeframe [5] - If the company fails to disclose the 2024 annual report within two months of the suspension, it will face delisting risk warnings [5] Group 6 - Huakang Clean has pre-won a project worth RMB 167 million [6] - Tongguang Cable has pre-won a procurement project from the State Grid valued at RMB 142 million [6] - Fengmao Co. has increased its investment in a production base in Thailand to RMB 26 million [6] Group 7 - Huaren Pharmaceutical's wholly-owned subsidiary has obtained a medical device registration certificate for wound dressings [7] Group 8 - Major shareholders of Kairun Co. plan to reduce their holdings by no more than 9 million shares [10] - CITIC Securities has completed its reduction plan for China Gold [10] - The reduction plan for Hengfeng Information's director and vice president has been completed [10]

Core Viewpoint - Several listed companies in the Shanghai and Shenzhen markets have announced significant updates, including stock suspensions, name changes, and financial adjustments, which may present both opportunities and risks for investors [4][5][8][10]. Group 1: Stock Suspension and Changes - ST Xinchao will suspend its stock from May 6, 2025, due to the inability to disclose audited financial reports within the legal timeframe, with a risk of delisting if reports are not provided within two months [4]. - Wolong Real Estate plans to change its stock name to "Wolong New Energy" to align with national carbon neutrality policies and explore new profit growth areas [5]. Group 2: Financial and Operational Updates - Dongzhu Ecology clarified that it holds only a 10% stake in Dilos AI Technology and has no substantial business cooperation with it, indicating potential uncertainties in future performance [6][7]. - Haitian Flavor Industry has received approval from the China Securities Regulatory Commission for its H-share issuance, planning to issue up to 710.52 million shares for overseas listing, though uncertainties remain [8]. - Fudan Zhangjiang announced a price reduction of at least 35% for its Doxorubicin Liposome Injection, which generated approximately RMB 210 million in sales in 2024, accounting for 29% of total revenue, potentially leading to losses in 2025 [10]. Group 3: Shareholding and Financing Activities - Jiangbolong's major shareholder, the National Integrated Circuit Industry Investment Fund, plans to reduce its stake by up to 1% through market transactions between May 27 and August 26, 2025, without affecting control [12][13]. - Cambrian Technology intends to raise no more than RMB 4.98 billion through a private placement to fund projects related to large model chip and software platforms and to supplement working capital [14]. - Jinzhen Co. plans to sell up to 5 million shares from its repurchased stock, which amounts to 50% of the total repurchased shares, to maintain company value and shareholder interests [15]. Group 4: Major Contracts and Procurement Wins - Aolaide's subsidiary signed a sales contract worth RMB 655 million with Chengdu BOE Display Technology, expected to positively impact the company's performance in 2025 and 2026 [16]. - Tongguang Cable is a candidate for two procurement projects from the State Grid Corporation, with a total expected bid amount of RMB 142 million, representing approximately 5.49% of the company's total revenue for 2024 [17].

经本公司审慎研究，决定自2025年5月1日起按照各省份对于未中选产品的规则和要求，陆续调整、梯度 降低该药物的市场零售价格，相比此前中标价格降价幅度不低于 35%。 本次价格调整后，预计对该药物2025年第二季度及后续执行期间的销售收入产生不利影响。鉴于该药物 价格调整及本次集采未中选后销售量下滑等因素，预计将导致该药物2025年度销售收入同比下降，其对 本集团实际业绩影响最终以本集团经审计的2025年度财务数据为准。本公司将依据香港联合交易所有限 公司证券上市规则及其他相关规则及规定，及时就本集团的财务表现另行刊发公告。 未来，本公司将继续维持与国内外现有主要供应商的长期合作;确保生产制造体系团队稳定;强化生产全 过程质量控制。本公司秉持对患者负责的经营理念，将一如既往保障药品质量稳定可靠。 本公司将持续关注省级、直辖市等地方销售政策，继续梳理优化营销网络，研究各省医保政策、商保政 策及招标方案;积极开发空白医疗机构，加强在民营医院、盈利性医疗机构等终端市场的开拓力度，提 升终端服务能力;通过临床疗效数据、患者教育等学术推广等方式强化产品差异化优势，提升品牌影响 力。 本集团将持续加大研发投入，加速研发项目 ...

Group 1 - ST Xinchao is unable to disclose its audited annual report for 2024 and Q1 2025 by the legal deadline, leading to a stock suspension starting May 6, 2025. If the report is not disclosed within two months, the stock will face delisting risk warning [3] - Wolong Real Estate plans to change its stock name to "Wolong New Energy" to align with national "dual carbon" policies and to explore new profit growth points in the renewable energy sector [4] - Dongzhu Ecology clarifies that it only holds a 10% stake in Dilos AI Technology and has no substantial business cooperation with it, as Dilos is still in its early stages of development [5] Group 2 - Haitian Flavor Industry has received approval from the China Securities Regulatory Commission for its H-share issuance, planning to issue up to 710.52 million shares for listing on the Hong Kong Stock Exchange, though uncertainties remain [6] - Jiawei New Energy's controlling shareholder received a warning letter from the Shenzhen Securities Regulatory Bureau for failing to fulfill a commitment to increase shareholding by at least 60 million yuan [7] - Fudan Zhangjiang will reduce the market retail price of its Doxorubicin Liposome Injection by no less than 35% starting May 1, 2025, which may negatively impact its sales revenue and lead to potential losses for this product in 2025 [8] Group 3 - Tongguang Cable is a pre-selected candidate for two procurement projects from the State Grid Corporation, with a total expected bid amount of 142 million yuan, representing approximately 5.49% of the company's total revenue for 2024 [12]